DIA521.44+3.00 0.58%
SPY750.33-4.50 -0.60%
QQQ729.86-14.14 -1.90%

RA Capital Management acquires Artiva Biotherapeutics common shares worth $8.19 million

PUBT·06/11/2026 23:37:10
Listen to the news
RA Capital Management acquires Artiva Biotherapeutics common shares worth $8.19 million
  • RA Capital Management, a director-level 10% owner, increased its Artiva Biotherapeutics common stock position through open-market purchases.
  • Stake rose to 16,231,717 shares held indirectly.
  • Buying activity was reported at prices around USD 6.91, USD 7, USD 7.91 per share.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001231919-26-000625), on June 11, 2026, and is solely responsible for the information contained therein.

Contact Us

Contact Number :+852 3852 8500
Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hk
Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hk
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2026 Webull Securities Limited. All rights reserved.